Navigating The Diverse Antibody Pipeline With Chromatography Innovations

Molecular diversity is increasing rapidly for biotherapeutics, and so also for monoclonal antibodies (mAbs). Of the ever-growing mAb area, variants such as bispecific antibodies, fragments, and antibody–drug conjugates form as much of a quarter of projects in the pipeline.

To help make the most of these new therapeutic possibilities, manufacturing and process development technologies must also evolve. For antibody variants, conventional purification protocols aren’t always suitable — some variants need new ligands, new base matrices, or new chromatography systems, or they have different regulatory requirements, or application needs.

Choosing a suitable resin for your purification needs doesn’t have to be daunting. Watch this video to learn more about how to select the right resin for your antibody variant purification project.